Anti-EGFR Targeted Monoclonal Antibody Isotype Influences Antitumor Cellular Immunity in Head and Neck Cancer Patients

作者：Trivedi, Sumita; Srivastava, Raghvendra M.; Concha-Benavente, Fernando; Ferrone, Soldano; Garcia-Bates, Tatiana M.; Li, Jing; Ferris, Robert L.^*

来源：Clinical Cancer Research, 2016, 22(21): 5229-5237.

DOI：10.1158/1078-0432.CCR-15-2971

• GROWTH-FACTOR RECEPTOR
• METASTATIC COLORECTAL-CANCER
• LABEL PHASE-2 TRIAL
• WILD-TYPE KRAS
• CHEMOTHERAPY PLUS
• RANDOMIZED-TRIAL
• NATURAL-KILLER
• CETUXIMAB
• PANITUMUMAB
• CARCINOMA

Purpose: EGF receptor (EGFR) is highly overexpressed on several cancers and two targeted anti-EGFR antibodies which differ by isotype are FDA-approved for clinical use. Cetuximab (IgG1 isotype) inhibits downstream signaling of EGFR and activates antitumor, cellular immune mechanisms. As panitumumab (IgG2 isotype) may inhibit downstream EGFR signaling similar to cetuximab, it might also induce adaptive immunity.
Experimental Design: We measured in vitro activation of cellular components of the innate and adaptive immune systems. We also studied the in vivo activation of components of the adaptive immune system in patient specimens from two recent clinical trials using cetuximab or panitumumab.
Results: Both monoclonal antibodies (mAb) primarily activate natural killer (NK) cells, although cetuximab is significantly more potent than panitumumab. Cetuximab-activated neutrophils mediate antibody-dependent cellular cytotoxicity (ADCC) against head and neck squamous cell carcinomas (HNSCC) tumor cells, and interestingly, this effect was Fc gamma RIIa- and Fc gamma RIIIa genotype-dependent. Panitumumab may activate monocytes through CD32 (Fc gamma RIIa); however, monocytes activated by either mAb are not able to mediate ADCC. Cetuximab enhanced dendritic cell (DC) maturation to a greater extent than panitumumab, which was associated with improved tumor antigen cross-presentation by cetuximab compared with panitumumab. This correlated with increased EGFR-specific cytotoxic CD8(+) T cells in patients treated with cetuximab compared with those treated with panitumumab.
Conclusions: Although panitumumab effectively inhibits EGFR signaling to a similar extent as cetuximab, it is less effective at triggering antitumor, cellular immune mechanisms which may be crucial for effective therapy of HNSCC.

• 出版日期2016-11-1
• 单位清华大学